Showing 5851-5860 of 9808 results for "".
- New Analysis Ranks Tremfya Highest Among PsA Treatments for Skin Clearancehttps://practicaldermatology.com/news/new-analysis-ranks-tremfya-highest-among-psa-treatments-for-skin-clearance/2461054/Tremfya® (guselkumab) ranks highest for skin clearance, based on Psoriasis (PsO) Area Severity Index (PASI) 90 response, among 23 psoriatic arthritis (PsA) treatment regimens, results of a newly reported Network Meta-Analysis (NMA) show. In terms of joint inflammation
- Skyrizi Gets Psoriatic Arthritis Indicationhttps://practicaldermatology.com/news/skyrizi-gets-psoriatic-arthritis-indication/2461049/Skyrizi® (risankizumab-rzaa) from AbbVie is now approved for the treatment of adults with active psoriatic arthritis (PsA). FDA approval is supported by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated the efficacy a
- Survey Reveals Impact of AGA on Affected Men, Interest in New Therapieshttps://practicaldermatology.com/news/survey-reveals-impact-of-aga-on-affected-men-interest-in-new-therapies/2461046/Nearly two-thirds (64%) of men with androgentic alopecia (AGA) say the condition has a negative affect on their lives, yet more than half (56%) have never sought treatment for the condition, results of a survey show. Findings from the survey, conducted on behalf of
- Scientis: Mikki Bey Crawford Named US VP and General Manager, Aesthetic Dermatologyhttps://practicaldermatology.com/news/scientis-mikki-bey-crawford-named-us-vp-and-general-manager-aesthetic-dermatology/2461045/Mikki Bey Crawford is now US Vice President and General Manager, Aesthetic Dermatology for Scientis. In her new role, she will lead the sales and marketing teams to accelerate the growth of Cyspera® in the US. "We are so pleased t
- Phase 3 Data Show Benefit of Dupixent to Reduce Itch in Prurigo Nodularishttps://practicaldermatology.com/news/phase-3-data-show-benefit-of-dupixent-to-reduce-itch-in-prurigo-nodularis/2461044/Dupixent® (dupilumab) from Sanofi and Regeneron significantly reduced itch and skin lesions compared to placebo at 24 weeks in a phase 3 trial in adults with uncontrolled prurigo nodularis. The new data confirm positive results
- New Patient Satisfaction Data from Dermavant's PSOARING 3 Trial of Tapinarof in Adults with Plaque Psoriasishttps://practicaldermatology.com/news/new-patient-satisfaction-data-from-dermavants-psoaring-3-trial-of-tapinarof-in-adults-with-plaque-psoriasis/2461043/Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof
- Is CBG the Next CBD for Skincare?https://practicaldermatology.com/news/is-cbg-the-next-cbd-for-skincare/2461042/Cannabigerol (CBG) shows antioxidant, anti-inflammatory, and skin health-boosting activity in lab assays and provides similar benefits when applied topically to human skin, according to new research. In a single-blind c
- Scleroderma Research Foundation Announces $1.5M Matching Gift in Honor of Bob Sagethttps://practicaldermatology.com/news/scleroderma-research-foundation-announces-15m-matching-gift-in-honor-of-bob-saget/2461035/The Scleroderma Research Foundation (SRF) announced a $1.5M matching gift in honor of Bob Saget, a SRF
- Drug Combination Boosts Progression-free Survival in Advanced Melanomahttps://practicaldermatology.com/news/drug-combination-boosts-progression-free-survival-in-advanced-melanoma/2461027/Combining relatlimab and nivolumab (Opdivo) may double progression-free survival in patients with advanced melanoma, according to a new study in the New England Journal of Medicine. Relatlimab, which blocks
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are